NUS Medicine’s Clinical Imaging Research Centre (CIRC), a leading academic centre for advanced biomedical imaging within the National University Health System (NUHS), and Cyclotek, one of Australia and New Zealand’s premier radiopharmaceutical manufacturers and distributors, today announced a strategic collaboration to enhance radiopharmaceutical development, clinical trials, and precision diagnostic capability across Singapore and the wider ASEAN region.
The partnership brings together CIRC’s world-class imaging research and clinical trial infrastructure with Cyclotek’s established manufacturing network, GMP capabilities, and access to proprietary investigational radiopharmaceuticals. Together, the organisations aim to create a stronger, more connected, and innovation-ready radiopharmaceutical ecosystem that can deliver earlier diagnosis, more accurate disease characterisation, and improved access to next-generation diagnostic and therapeutic agents.
The collaboration will form a pathway to:
Professor Pek-Lan Khong, Director of the Clinical Imaging Research Centre (CIRC) at NUS Medicine, said “This collaboration is a strategic imperative for biomedical innovation in Singapore. By exploring how our research capabilities and clinical trial infrastructure can be combined with Cyclotek’s advanced manufacturing network and proven GMP quality system, we hope to create a powerful conduit to accelerate promising new radiopharmaceutical research from our Academic Cyclotron and GMP radiopharmaceutical facility to clinical trials in Singapore and the ASEAN region, and finally, translating it into clinical practice for the benefit of patients. This effort will not only elevate the standard of patient care here but will also foster significant co-investment in grant-focused research and build a talent pipeline through specialized training programs”
Cyclotek supplies more than 150,000 patient doses annually across Australia and New Zealand and operates one of the region’s most advanced radiopharmaceutical manufacturing networks. The collaboration supports Singapore’s long-term ambitions in precision medicine and creates new pathways to make emerging radioligand therapies more accessible across Southeast Asia.
Mr Jon Evans, CEO of Cyclotek International, said “Cyclotek is deeply committed to ensuring reliable, high-quality access to life-changing radiopharmaceuticals. Our partnership with NUS and NUHS is foundational to realising this vision in Southeast Asia. This joint effort aims to increase the utility and availability of these products for hospitals, clinicians, and patients in Singapore and right across the ASEAN health and economic community, supporting next-generation molecular imaging and therapy essential for individualised diagnosis and treatment of serious diseases. This is a compelling value proposition that reduces long-term social and economic costs.”
As the collaboration develops, both organisations will also explore future opportunities to support talent development and specialised training in radiopharmaceutical science and advanced imaging, strengthening the long-term workforce capabilities essential for a sustainable regional ecosystem.
The partnership is expected to increase access to PET radiopharmaceuticals and radionuclide therapies for clinical research and development, support evaluation of emerging diagnostic and therapeutic agents, and improve supply reliability for investigational products. This will aid the earlier detection and characterisation of cancer, neurological diseases, and other serious conditions, contributing to better patient outcomes and improved health system resilience across ASEAN.
The translation of the Cyclotek accumulated expertise, developed across the last 25 years of GMP manufacturing operations, captured within our Pharmaceutical Quality System will enable CIRC and our other participating ASEAN partners to more consistently produce high quality new and emerging radiopharmaceuticals with greater efficiency.
Media Contact:
Paul Higgins
+61423 901 304
Codex Communications (on behalf of Cyclotek)
contact@codexcomms.com.au
Background about Cyclotek:
Cyclotek is a leading radiopharmaceutical company supplying advanced diagnostic and therapeutic products for clinical use and clinical trials across Australia and New Zealand. With a multi-site GMP manufacturing network and more than two decades of operational excellence, Cyclotek provides reliable access to high-quality PET radiopharmaceuticals for over 150,000 patients each year.
The company specialises in enabling earlier and more precise diagnosis through innovative PET tracers that provide patient-specific insights into cancer, neurological diseases, and other serious conditions. These tracers help clinicians detect disease earlier, assess progression more accurately, and plan treatment with greater confidence. When paired with emerging radionuclide therapies, they support a comprehensive, non-invasive approach to personalised disease management.
Cyclotek is also deeply committed to research, translation, and the development of new radiopharmaceuticals, working with global partners, universities, and clinical trial sponsors to expand access to next-generation diagnostic and therapeutic agents. This includes supporting First-in-Human studies, specialised manufacturing requirements, and technology transfer for investigational compounds.
Beyond manufacturing, Cyclotek serves as a regional capability partner—focused on quality, safety, supply resilience, and collaborative innovation. The company’s mission is to strengthen radiopharmaceutical access, contribute to more cost-effective and patient-centred healthcare, and help build the infrastructure required for precision medicine across the Asia-Pacific region.
[contact-form-7 id=”714″ title=”Update Form”]
